fruquintinib (Rx)

Brand and Other Names:Fruzaqla

Dosing & Uses

AdultPediatric

Dosage Forms & Strengths

capsule

  • 1mg
  • 5mg

Colorectal Cancer

Indicated for treatment of adults with metastatic colorectal cancer (mCRC) who have been previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if RAS wild-type and medically appropriate, an anti-EGFR therapy

Each cycle is 28 days

5 mg PO qDay on first 21 days of each cycle

Continue until disease progression or unacceptable toxicity

Dosage Modifications

Recommended dose reductions

  • First dose reduction: 4 mg PO qDay
  • Second dose reduction: 3 mg PO qDay
  • Unable to tolerate 3 mg PO qDay: Permanently discontinue

Hypertension

  • Grade 3 that persists despite optimal antihypertensive therapy: Withhold until blood pressure (BP) elevation fully resolves or recovers to Grade 1, then resume at next lower dose level
  • Grade 4: Permanently discontinue

Hemorrhagic events

  • Grade 2: Withhold until bleeding fully resolves or recovers to Grade 1, resume at next lower dose level
  • Grade 3 or 4: Permanently discontinue

Hepatotoxicity

  • Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >3x upper limit of normal (ULN) with total bilirubin (TB) ≤2x ULN: Withhold and monitor AST/ALT and TB until resolution to Grade 1 or baseline, then resume at next lower dose level
  • Permanently discontinue
    • ALT/AST >3x ULN WITH bilirubin >2x ULN (with no cholestasis or hemolysis)
    • ALT/AST >20x ULN OR bilirubin >10x ULN

Proteinuria

  • ≥2 grams/24 hr: Withhold until proteinuria fully resolves or <1 gram/24 hr, resume at next lower dose level once recovered
  • Permanently discontinue for nephrotic syndrome or if proteinuria does not recover to <1 gram/24 hr

Palmoplantar erythrodysesthesia

  • Withhold and initiate supportive treatment
  • Grade 2: If fully resolves or recovers to Grade 1, resume at same dose level
  • Grade 3: If fully resolves or recovers to Grade 1, resume at next lower dose level

Other adverse reactions

  • Grade 3: Withhold until toxicity fully resolves or recovers to Grade 1, resume at next lower dose level
  • Grade 4: Discontinue; consider resuming at next lower dose level only if toxicity is non–life-threatening and fully resolves or recovers to Grade 1 and potential benefit outweighs risks

Strong or moderate CYP3A4 inducers

  • Avoid coadministration of strong or moderate CYP3A4 inducers with fruquintinib

Renal impairment

  • Mild or moderate (CrCl 30-89 mL/min): No dosage adjustment necessary

Hepatic impairment

  • Mild (total bilirubin ≤ULN with AST >ULN or total bilirubin >1-1.5x ULN with any AST): No dosage adjustment necessary
  • Moderate (total bilirubin >1.5x to <3x ULN and any AST): Not studied
  • Severe hepatic impairment (total bilirubin >3x ULN and any AST): Fruquintinib not recommended

Dosing Considerations

Verify pregnancy status for females of childbearing potential

Safety and efficacy not established

Next:

Interactions

Interaction Checker

and fruquintinib

No Results

     activity indicator 
    No Interactions Found
    Interactions Found

    Contraindicated

      Serious - Use Alternative

        Significant - Monitor Closely

          Minor

            All Interactions Sort By:
             activity indicator 

            Contraindicated (0)

              Serious - Use Alternative (42)

              • amobarbital

                amobarbital will decrease the level or effect of fruquintinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. If coadministration with moderate CYP3A4 inducers is unavoidable, continue to administer fruquintinib at recommended dosage.

              • apalutamide

                apalutamide will decrease the level or effect of fruquintinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.

              • armodafinil

                armodafinil will decrease the level or effect of fruquintinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. If coadministration with moderate CYP3A4 inducers is unavoidable, continue to administer fruquintinib at recommended dosage.

              • belzutifan

                belzutifan will decrease the level or effect of fruquintinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. If coadministration with moderate CYP3A4 inducers is unavoidable, continue to administer fruquintinib at recommended dosage.

              • bexarotene

                bexarotene will decrease the level or effect of fruquintinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. If coadministration with moderate CYP3A4 inducers is unavoidable, continue to administer fruquintinib at recommended dosage.

              • bosentan

                bosentan will decrease the level or effect of fruquintinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.

              • butabarbital

                butabarbital will decrease the level or effect of fruquintinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. If coadministration with moderate CYP3A4 inducers is unavoidable, continue to administer fruquintinib at recommended dosage.

              • butalbital

                butalbital will decrease the level or effect of fruquintinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. If coadministration with moderate CYP3A4 inducers is unavoidable, continue to administer fruquintinib at recommended dosage.

              • carbamazepine

                carbamazepine will decrease the level or effect of fruquintinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.

              • cenobamate

                cenobamate will decrease the level or effect of fruquintinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. If coadministration with moderate CYP3A4 inducers is unavoidable, continue to administer fruquintinib at recommended dosage.

              • dabrafenib

                dabrafenib will decrease the level or effect of fruquintinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. If coadministration with moderate CYP3A4 inducers is unavoidable, continue to administer fruquintinib at recommended dosage.

              • duvelisib

                duvelisib will decrease the level or effect of fruquintinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. If coadministration with moderate CYP3A4 inducers is unavoidable, continue to administer fruquintinib at recommended dosage.

              • efavirenz

                efavirenz will decrease the level or effect of fruquintinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. If coadministration with moderate CYP3A4 inducers is unavoidable, continue to administer fruquintinib at recommended dosage.

              • elagolix

                elagolix will decrease the level or effect of fruquintinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. If coadministration with moderate CYP3A4 inducers is unavoidable, continue to administer fruquintinib at recommended dosage.

              • encorafenib

                encorafenib will decrease the level or effect of fruquintinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. If coadministration with moderate CYP3A4 inducers is unavoidable, continue to administer fruquintinib at recommended dosage.

              • enzalutamide

                enzalutamide will decrease the level or effect of fruquintinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.

              • eslicarbazepine acetate

                eslicarbazepine acetate will decrease the level or effect of fruquintinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. If coadministration with moderate CYP3A4 inducers is unavoidable, continue to administer fruquintinib at recommended dosage.

              • etrasimod

                etrasimod, fruquintinib. Either increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Risk of additive immune system effects with etrasimod has not been studied in combination with antineoplastic, immune-modulating, or noncorticosteroid immunosuppressive therapies. Avoid coadministration during and in the weeks following administration of etrasimod.

              • etravirine

                etravirine will decrease the level or effect of fruquintinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. If coadministration with moderate CYP3A4 inducers is unavoidable, continue to administer fruquintinib at recommended dosage.

              • fosphenytoin

                fosphenytoin will decrease the level or effect of fruquintinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.

              • ivosidenib

                ivosidenib will decrease the level or effect of fruquintinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. If coadministration with moderate CYP3A4 inducers is unavoidable, continue to administer fruquintinib at recommended dosage.

              • lorlatinib

                lorlatinib will decrease the level or effect of fruquintinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. If coadministration with moderate CYP3A4 inducers is unavoidable, continue to administer fruquintinib at recommended dosage.

              • lumacaftor/ivacaftor

                lumacaftor/ivacaftor will decrease the level or effect of fruquintinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.

              • mavacamten

                mavacamten will decrease the level or effect of fruquintinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. If coadministration with moderate CYP3A4 inducers is unavoidable, continue to administer fruquintinib at recommended dosage.

              • mitapivat

                mitapivat will decrease the level or effect of fruquintinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. If coadministration with moderate CYP3A4 inducers is unavoidable, continue to administer fruquintinib at recommended dosage.

              • mitotane

                mitotane will decrease the level or effect of fruquintinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.

              • mobocertinib

                mobocertinib will decrease the level or effect of fruquintinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. If coadministration with moderate CYP3A4 inducers is unavoidable, continue to administer fruquintinib at recommended dosage.

              • modafinil

                modafinil will decrease the level or effect of fruquintinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. If coadministration with moderate CYP3A4 inducers is unavoidable, continue to administer fruquintinib at recommended dosage.

              • nafcillin

                nafcillin will decrease the level or effect of fruquintinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. If coadministration with moderate CYP3A4 inducers is unavoidable, continue to administer fruquintinib at recommended dosage.

              • olutasidenib

                olutasidenib will decrease the level or effect of fruquintinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. If coadministration with moderate CYP3A4 inducers is unavoidable, continue to administer fruquintinib at recommended dosage.

              • pentobarbital

                pentobarbital will decrease the level or effect of fruquintinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. If coadministration with moderate CYP3A4 inducers is unavoidable, continue to administer fruquintinib at recommended dosage.

              • pexidartinib

                pexidartinib will decrease the level or effect of fruquintinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. If coadministration with moderate CYP3A4 inducers is unavoidable, continue to administer fruquintinib at recommended dosage.

              • phenobarbital

                phenobarbital will decrease the level or effect of fruquintinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.

              • phenytoin

                phenytoin will decrease the level or effect of fruquintinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.

              • primidone

                primidone will decrease the level or effect of fruquintinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.

              • rifabutin

                rifabutin will decrease the level or effect of fruquintinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. If coadministration with moderate CYP3A4 inducers is unavoidable, continue to administer fruquintinib at recommended dosage.

              • rifampin

                rifampin will decrease the level or effect of fruquintinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.

              • rifapentine

                rifapentine will decrease the level or effect of fruquintinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. If coadministration with moderate CYP3A4 inducers is unavoidable, continue to administer fruquintinib at recommended dosage.

              • secobarbital

                secobarbital will decrease the level or effect of fruquintinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. If coadministration with moderate CYP3A4 inducers is unavoidable, continue to administer fruquintinib at recommended dosage.

              • sotorasib

                sotorasib will decrease the level or effect of fruquintinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. If coadministration with moderate CYP3A4 inducers is unavoidable, continue to administer fruquintinib at recommended dosage.

              • St John's Wort

                St John's Wort will decrease the level or effect of fruquintinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.

              • telotristat ethyl

                telotristat ethyl will increase the level or effect of fruquintinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. If coadministration with moderate CYP3A4 inducers is unavoidable, continue to administer fruquintinib at recommended dosage.

              Monitor Closely (1)

              • warfarin

                fruquintinib, warfarin. Other (see comment). Use Caution/Monitor. Comment: Fruquintinib may cause serious hemorrhagic events. Monitor INR in patients receiving anticoagulants.

              Minor (0)

                Previous
                Next:

                Adverse Effects

                >10%

                All grades

                • Creatinine increased (87%)
                • Hypertension (38-61%)
                • Proteinuria (18-55%)
                • Triglycerides increased (53%)
                • Fatigue (53%)
                • Palmoplantar erythrodysesthesia (19-49%)
                • Glucose increased (43%)
                • AST increased (36-42%)
                • Alkaline phosphatase increased (20-40%)
                • Bilirubin increased (30-39%)
                • Dysphonia (38%)
                • Cholesterol increased (37%)
                • Albumin decreased (35%)
                • Sodium decreased (33-35%)
                • ALT increased (33-34%)
                • Stomatitis (31-33%)
                • Lymphocytes decreased (30%)
                • Platelets decreased (29-30%)
                • Abdominal pain (25-29%)
                • Hemorrhage (28%)
                • Urate increased (26%)
                • Calcium decreased (25%)
                • Diarrhea (24-25%)
                • Hemoglobin decreased (23%)
                • Musculoskeletal pain (16-22%)
                • Potassium decreased (22%)
                • Hypothyroidism (17-21%)
                • Activated partial thromboplastin time (aPTT) increased (21%)
                • Anorexia (21%)
                • Magnesium increased (20%)
                • Dysphonia (18%)
                • Back pain (15%)
                • Arthralgia (11%)

                Grade 3 or 4

                • Urate increased (26%)
                • Hypertension (14-23%)
                • Fatigue (12%)
                • Palmoplantar erythrodysesthesia (6-11%)

                1-10%

                All grades

                • Throat pain (10%)
                • Urinary tract infection (4.6%)
                • Epistaxis (3.9%)
                • Proctalgia (3.5%)
                • Pneumonia (2.4%)
                • Albumin decreased (1.6%)
                • Gastrointestinal hemorrhage (1.5%)
                • Gastrointestinal perforation (1.3%)

                Grade 3 or 4

                • Bilirubin increased (4.7-7%)
                • Sodium decreased (1.1-6%)
                • ALT increased (2.2-5%)
                • Proteinuria (1.8-4.7%)
                • AST increased (3.6-4.3%)
                • Alkaline phosphatase increased (1.6-4.3%)
                • Platelets decreased (3.6%)
                • Abdominal pain (3.5-4%)
                • Diarrhea (3.6-3.7%)
                • Triglycerides increased (2.8%)
                • aPTT increased (2.7%)
                • Stomatitis (0.7-2.2%)
                • Cholesterol increased (1.9%)
                • Back pain (1.8%)
                • Potassium decreased (1.8%)
                • Anorexia (1.4%)
                • Musculoskeletal pain (1.1-2.2%)
                • Hemorrhage (1.1%)
                • Glucose increased (1.1%)

                <1%

                All grades

                • Thrombotic microangiopathy (0.2%)
                • Posterior reversible encephalopathy syndrome (0.2%)

                Grade 3 or 4

                • Arthralgia (0.9%)
                • Hemoglobin decreased (0.7%)
                • Creatinine increased (0.7%)
                • Magnesium decreased (0.5%)
                • Hypothyroidism (0.4%)
                • Calcium decreased (0.4%)
                • Lymphocytes decreased (0.2%)
                Previous
                Next:

                Warnings

                Contraindications

                None

                Cautions

                May cause serious hemorrhagic events, which may be fatal; permanently discontinue if severe or life-threatening hemorrhaging occurs; monitor international normalized ratio (INR) levels in patients receiving anticoagulants

                Increased risk of infections reported, including fatal infections; withhold for Grade 3 or 4 infections, or worsening infection of any grade, then resume at same dose when infection has resolved

                Gastrointestinal (GI) perforation reported; permanently discontinue if GI perforation or fistula develops

                Palmoplantar erythrodysesthesia may occur; based on severity, withhold and then resume at same or reduced dose

                Posterior reversible encephalopathy syndrome (PRES) reported; PRES is a syndrome of subcortical vasogenic edema diagnosed by characteristic finding on MRI; evaluate for PRES if seizures, headache, visual disturbances, confusion, or altered mental function develops; discontinue if PRES develops

                May increase risk of arterial thromboembolic events; carefully consider initiating in patients with recent history of thromboembolic events; discontinue if arterial thromboembolism develops

                1-mg capsules contain FD&C yellow No. 5 (tartrazine), which may cause allergic-type reactions (including bronchial asthma) in certain susceptible persons

                Based on animal studies and its mechanism of action, fetal harm may occur when administered to pregnant females

                Hypertension

                • May cause hypertension
                • Median time from first dose to hypertension onset was 14 days
                • Do not initiate unless BP is adequately controlled
                • Monitor BP weekly for first month, at least monthly thereafter, and as clinically indicated
                • Initiate or adjust antihypertensive therapy as appropriate
                • Withhold, reduce dose, or permanently discontinue based on hypertension severity

                Hepatotoxicity

                • Liver injury may occur
                • Median time from first dose to onset of elevated liver enzymes was 29 days
                • Monitor liver function tests (ALT, AST, and bilirubin) before initiation and periodically during treatment
                • Temporarily hold and then reduce or permanently discontinue depending on severity and persistence of hepatotoxicity

                Impaired wound healing

                • Impaired wound healing can occur in patients who receive vascular endothelial growth factor (VEGF) signaling pathway inhibitors
                • Do not administer for at least 2 weeks before major surgery
                • Do not administer for at least 2 weeks after major surgery and until adequate wound healing
                • Safety of resuming treatment after wound healing complications resolve has not been established

                Drug interaction overview

                • Substrate of CYP3A4
                • Strong or moderate CYP3A inducers
                  • Strong CYP3A4 inducers: Avoid use
                  • For moderate CYP3A4 inducers, avoid use if possible
                  • If unavoidable, continue to administer at recommended dosage
                  • Strong or moderate CYP3A inducers may decrease fruquintinib levels and efficacy
                Previous
                Next:

                Pregnancy & Lactation

                Pregnancy

                Based on animal studies and its mechanism of action, fetal harm may occur when administered to pregnant females

                Contraception

                • Females of childbearing potential and males with female partners of childbearing potential: Use effective contraception during treatment and for 2 weeks after last dose

                Animal data

                • In pregnant rats, oral administration during organogenesis resulted in teratogenicity and embryo lethality at exposures below clinical exposure

                Lactation

                No data are available regarding presence of fruquintinib or its metabolites in human milk or its effects on a breastfed child or on milk production

                Advise women not to breastfeed during treatment and for 2 weeks after last dose

                Pregnancy Categories

                A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

                B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

                C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

                D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

                X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

                NA: Information not available.

                Previous
                Next:

                Pharmacology

                Mechanism of Action

                Oral, small molecule inhibitor of vascular endothelial growth factor receptors (VEGFRs), with potential anti-angiogenic and antineoplastic activities

                Fruquintinib inhibits VEGF-induced phosphorylation of VEGFRs 1, 2, and 3, which may result in inhibition of migration, proliferation, and survival of endothelial cells; micro-vessel formation; and tumor cell proliferation, resulting in tumor cell death

                Absorption

                Peak plasma concentration: 300 ng/mL

                Peak plasma time: ~2 hr

                AUC: 5,880 ng⋅hr/mL

                Steady-state achieved at 14 days

                Distribution

                Vd: 46 L

                Protein bound: ~95%

                Metabolism

                Primarily eliminated by CYP450 and non-CYP450 (ie, sulfation and glucuronidation) metabolism

                Metabolized by CYP3A and to a lesser extent CYP2C8, CYP2C9, and CYP2C19

                Elimination

                Clearance: 14.8 mL/min

                Half-life: 42 hr

                Excretion: 60% (urine, 0.5% unchanged); 30% (feces, 5% unchanged)

                Previous
                Next:

                Administration

                Oral Administration

                Take with or without food at approximately the same time each day

                Swallow capsule whole

                Missed or vomited dose

                • <12 hr since missed dose: Take missed dose; do not take 2 doses on the same day to make up for a missed dose
                • Vomited dose: Do not take additional dose, but continue with next dose at next scheduled time

                Storage

                Store at 20-25ºC (68-77ºF), excursion permitted to 15-30ºC (59-86°F) permitted

                Any unused medicinal product or waste material should be disposed of in accordance with local requirements

                Previous
                Next:

                Images

                No images available for this drug.
                Previous
                Next:

                Patient Handout

                A Patient Handout is not currently available for this monograph.
                Previous
                Next:

                Formulary

                FormularyPatient Discounts

                Adding plans allows you to compare formulary status to other drugs in the same class.

                To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.

                Adding plans allows you to:

                • View the formulary and any restrictions for each plan.
                • Manage and view all your plans together – even plans in different states.
                • Compare formulary status to other drugs in the same class.
                • Access your plan list on any device – mobile or desktop.

                The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.

                Tier Description
                1 This drug is available at the lowest co-pay. Most commonly, these are generic drugs.
                2 This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.
                3 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.
                4 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
                5 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
                6 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
                NC NOT COVERED – Drugs that are not covered by the plan.
                Code Definition
                PA Prior Authorization
                Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
                QL Quantity Limits
                Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
                ST Step Therapy
                Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
                OR Other Restrictions
                Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
                Additional Offers
                Email to Patient

                From:

                To:

                The recipient will receive more details and instructions to access this offer.

                By clicking send, you acknowledge that you have permission to email the recipient with this information.

                Email Forms to Patient

                From:

                To:

                The recipient will receive more details and instructions to access this offer.

                By clicking send, you acknowledge that you have permission to email the recipient with this information.

                Previous
                Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.